The most important problems of implementing medical combination products to the market

By | 9 July 2021
A transdermal patch is a galenic form containing a reservoir with active ingredient that is freed gradually when attached to the skin. Its aim is for the pharmaceutical to enter the systemic circulation through the skin surface and not the medicine’s activity in the skin itself.

As we keep getting older and older, steadily we add more medicines in our daily lives, and for this motive, the patches that stick on the skin acquire an essential role to avoid problems because of a great consumption of medicines, especially in the old age, and also for your comfort.
Medicine-device combination products, such as transdermal patch, introduced a new dynamic on medical product evolution, regulatory authorization, and corporate cooperation that provide priceless lessons for the improvement of new generations of combination products. Inquiry show that the largest obstacle to initiate a new type of combination products is the creation of the supervisory center which would be to supervise its approval, and so the device contract. The first invention of a recent kind of combination product offers a learning chance for the supervisor and the sponsor. Once that the first solution is authorized, the leading supervisory center is determined, and the uncertainty about the whole kind of combination solutions is drastically diminished.

The benefactor pioneering a new class of combination products undertakes a principal role in reducing this uncertainty by recommending the decision on the most important purpose of the combination product. This decision influences the character of the enterprises that will drive the introduction of these inventions into the market.